摘要
内分泌治疗是雌激素受体阳性乳腺癌的治疗方法之一,治疗药物包括选择性雌激素受体调节剂(selective estrogen receptor modulator,SERM)、选择性雌激素受体下调剂(selective estrogen receptor downregulator,SERD)和芳香化酶抑制剂(aromatase inhibitor,AI)。肿瘤细胞对内分泌治疗药物的耐受性是限制内分泌治疗药物临床应用的关键因素之一,耐药性又分为固有性耐药和获得性耐药。获得性耐药的产生可能与雌激素受体(estrogen receptor,ER)、受体酪氨酸激酶(receptor tyrosine kinase,RTK)、磷脂酰肌醇-3-激酶(phosphatidylinositol-3-kinase,PI3K)等通路介导的ERα共激活因子的过度表达,细胞周期调节因子的异常表达等有关。本文主要对乳腺癌内分泌治疗耐药发生的机制以及应对策略进行综述。
Endocrine therapy is one of the treatment options for estrogen receptor-positive breast cancer.The therapeutic drugs include selective estrogen receptor modulators,selective estrogen receptor down-regulators and aromatase inhibitors.The resistance of tumor cells to endocrine therapy is one of the key factors limiting the clinical application of endocrine therapeutic drugs.Resistance includes intrinsic drug resistance and acquired drug resistance.The generation of acquired drug resistance may be related to the overexpression of ERα coactivators and the abnormal expression of cell cycle regulators mediated by ER,RTKs,PI3K and other pathways.This article mainly reviews the mechanism of breast cancer resistance to endocrine therapy and the treatment strategies.
作者
徐杨安泰
王美宸
缪晶茜
杨凤花
余亭瑶
周轶平
XU-YANG An-tai;WANG Mei-chen;MIAO Jin-qian;YANG Feng-hua;YU Ting-yao;ZHOU Yi-ping(School of Pharmaceutical Sciences&Yunnan Key Laboratory of Pharmacology for Natural Products,Kunming Medical University,Kunming 650500,China)
出处
《中国新药杂志》
CAS
CSCD
北大核心
2023年第12期1228-1232,共5页
Chinese Journal of New Drugs
基金
国家自然科学基金地区基金资助项目(81960739)
云南省科技厅-昆明医科大学应用基础研究联合专项(2019FE001(-193))
云南省科学技术院重大专项“生物资源数字化开发应用”(202002AA100007)。
关键词
乳腺癌
内分泌耐药
信号通路
机制
breast cancer
endocrine drug resistance
signaling pathway
mechanism
